$GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Healthcare
Sector
Biotechnology
Industry
Ryan Confer
CEO
15
Employees
$1.28
Current Price
$3.59M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $22.14 | 18 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $22.14 | 18 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $22.14 | 18 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 2 | $22.14 | 18 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Apr 14, 2026 | LONGNECKER BRENT M Director | Sale | 10 | $1.23 | $12.30 | View Details |
| Apr 14, 2026 | LONGNECKER BRENT M Director | Sale | 8 | $1.23 | $9.84 | View Details |
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$13.00
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history